What Catalysts Are Shaping the Changing Narrative for Ironwood Pharmaceuticals? [Yahoo! Finance]
Ironwood Pharmaceuticals: Today's Gains Seem Sustainable After Disastrous First Half Of 2025 [Seeking Alpha]
Ironwood Pharmaceuticals (NASDAQ:IRWD) had its price target raised by analysts at Wells Fargo & Company from $1.00 to $3.00. They now have an "equal weight" rating on the stock.
Ironwood Pharmaceuticals Non-GAAP EPS of $0.24 beats by $0.12, revenue of $122.06M beats by $46.36M [Seeking Alpha]
Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance